Beam Therapeutics (BEAM) Institutional Ownership
13F filers reported holding 34.7% of Beam Therapeutics (BEAM) shares as of Sep 30, 2026, across 149 filers.
- Held by 13F filers
- 34.7%
- Sep 30, 2026
- 13F filers
- 149
- quarter ended Sep 30, 2026
- 13F value
- $877.7M
- 35.9M shares
- Quarter's fund flow
- Mild distribution
- 18 new · 28 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 16, 2026 | Evans John M. | CEO | Acquired · Option exercise | 25,000 | $1.03 | ↗ |
| Oct 16, 2026 | Evans John M. | CEO | Disposed · Open-market sale | 25,000 | $23.98 | ↗ |
| Oct 16, 2026 | Evans John M. | CEO | Disposed · Option exercise | 25,000Stock Option (Right to Buy) | — | ↗ |
| Oct 15, 2026 | Evans John M. | CEO | Acquired · Option exercise | 25,000 | $1.03 | ↗ |
| Oct 15, 2026 | Evans John M. | CEO | Disposed · Open-market sale | 25,000 | $23.57 | ↗ |
| Oct 15, 2026 | Evans John M. | CEO | Disposed · Option exercise | 25,000Stock Option (Right to Buy) | — | ↗ |
| Oct 1, 2026 | Cavanagh Bethany J | SVP, Finance and Treasurer | Disposed · Open-market sale | 187 | $24.41 | ↗ |
| Jul 27, 2026 | Simon Amy | Chief Medical Officer | Disposed · Open-market sale | 16,667 | $25.74 | ↗ |
| Jun 30, 2026 | Simon Amy | Chief Medical Officer | Disposed · Open-market sale | 373 | $34.73 | ↗ |
| Jun 30, 2026 | Evans John M. | CEO | Acquired · Option exercise | 25,000 | $1.03 | ↗ |
| Jun 30, 2026 | Evans John M. | CEO | Disposed · Open-market sale | 23,100 | $34.26 | ↗ |
| Jun 30, 2026 | Evans John M. | CEO | Disposed · Open-market sale | 1,900 | $34.84 | ↗ |
| Jun 30, 2026 | Evans John M. | CEO | Disposed · Option exercise | 25,000Stock Option (Right to Buy) | — | ↗ |
| Jun 29, 2026 | Evans John M. | CEO | Acquired · Option exercise | 18,663 | $0.67 | ↗ |
| Jun 29, 2026 | Evans John M. | CEO | Acquired · Option exercise | 6,337 | $1.03 | ↗ |
| Jun 29, 2026 | Evans John M. | CEO | Disposed · Open-market sale | 13,421 | $35.13 | ↗ |
| Jun 29, 2026 | Evans John M. | CEO | Disposed · Open-market sale | 11,579 | $35.91 | ↗ |
| Jun 29, 2026 | Evans John M. | CEO | Disposed · Option exercise | 18,663Stock Option (Right to Buy) | — | ↗ |
| Jun 29, 2026 | Evans John M. | CEO | Disposed · Option exercise | 6,337Stock Option (Right to Buy) | — | ↗ |
| Jun 26, 2026 | FMR LLC | 10% owner | Disposed · Open-market sale | 251,488 | $35.26 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Beam Therapeutics do institutions hold?
13F filers reported holding 34.7% of Beam Therapeutics' shares as of Sep 30, 2026, across 149 filers.
How many 13F filers hold Beam Therapeutics?
Beam Therapeutics was held by 149 13F filers as of Sep 30, 2026.
Not investment advice.

